跳到正文
原文
Nature 健康护理主题·· 2026-10-19AI 评分55

印度市场上热稳定卡贝缩宫素注射剂的质量与短期稳定性评估

A post-marketing assessment of critical quality and short-term stability attributes of heat-stable carbetocin injection products marketed in India

AI 导读

一项发表于 Scientific Reports 的研究评估了印度两款热稳定卡贝缩宫素仿制药与原研药的质量和短期稳定性。所有产品在含量和总杂质方面均符合标准,但仿制药在 30°C 以上杂质生成速率更高,40°C 存放六个月后总杂质约 3.4%–3.6%,而原研药为 1.8%。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Intramuscular carbetocin injection has comparable efficacy to the first-line therapy, oxytocin injection, when used for prevention of postpartum haemorrhage, the leading cause of global maternal mortality. A novel heat-stable injectable formulation of carbetocin, first marketed in 2020, overcomes the requirement for refrigerated storage and aims to increase access to quality-assured uterotonic products in resource-limited settings where cold chain infrastructure is lacking or unreliable. Generic heat-stable carbetocin products have now emerged in India. In the context of widespread evidence that generic oxytocin injection products claiming stability outside of the cold chain do not meet stability requirements for non-refrigerated storage in hot and humid climates, this study is the first to assess the quality and stability of these carbetocin products. Two heat-stable generic carbetocin products were assessed in comparison to the innovator product for key quality attributes (assay, impurities and pH) and stability during a six-month program at temperatures ranging from 2 to 8 °C to 60 °C. All heat-stable products assessed met recognised quality standards for drug content (108.93% − 109.90%) and total impurities (0.57% − 0.85%). The generic products showed robust stability in terms of drug content, with no significant differences in degradation rates to the innovator product at all temperatures over the period tested. However, the rate of total impurity formation was higher than the innovator product at temperatures exceeding 30 °C, largely driven by hydrolytic degradation (e.g. total impurities after six months storage at 40 °C – generic 3.4–3.6%, innovator 1.8%). Impurity formation may be associated with the lower pH of these formulations (generic pH 4.7 vs. innovator pH 5.5) catalysing this degradation process. While long-term testing of multiple batches would be required for definitive conclusions, this study provides no indications of quality issues associated with the generic heat-stable carbetocin products based on the attributes tested. Furthermore, these products demonstrate similar stability to the innovator during short-term stability testing at their registered storage conditions (i.e. up to 30 °C).

Acknowledgements

The authors would like to acknowledge Ferring Pharmaceuticals for providing the innovator products assessed in this study. Ferring Pharmaceuticals had no involvement in any aspect of the study.

Funding

This study was funded through an unrestricted grant provided to the corresponding author from the Ripple Foundation, Sydney, Australia. The funder had no involvement in any aspect of the study.

Author information

Authors and Affiliations

  1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

    Pete Lambert, Matt Parsons & David A. Rudd

Authors

  1. Pete Lambert
  2. Matt Parsons
  3. David A. Rudd

Corresponding author

Correspondence to Pete Lambert.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lambert, P., Parsons, M. & Rudd, D.A. A post-marketing assessment of critical quality and short-term stability attributes of heat-stable carbetocin injection products marketed in India. Sci Rep (2026). https://doi.org/10.1038/s41598-026-76537-2

Download citation

  • Received: 10 February 2026

  • Accepted: 14 October 2026

  • Published: 19 October 2026

  • DOI: https://doi.org/10.1038/s41598-026-76537-2

Keywords

来源:Nature 健康护理主题 · nature.com